Early trial tests supercharged immune cells against tough liver cancer
NCT ID NCT07487402
Summary
This early-phase study is testing a new type of cell therapy called Meta10-GPC3 CAR-T in patients with advanced liver cancer that has returned or spread and cannot be surgically removed. The main goals are to see if the treatment is safe and to look for early signs that it can shrink tumors. Researchers will enroll about 27 adults whose liver cancer cells carry a specific marker called GPC3.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.